IN2012DN03042A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03042A
IN2012DN03042A IN3042DEN2012A IN2012DN03042A IN 2012DN03042 A IN2012DN03042 A IN 2012DN03042A IN 3042DEN2012 A IN3042DEN2012 A IN 3042DEN2012A IN 2012DN03042 A IN2012DN03042 A IN 2012DN03042A
Authority
IN
India
Prior art keywords
neuropeptide
obesity
diabetes
substituents
fragments
Prior art date
Application number
Other languages
English (en)
Inventor
Karin Conde-Knape
Waleed Danho
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03042A publication Critical patent/IN2012DN03042A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IN3042DEN2012 2009-10-13 2010-10-08 IN2012DN03042A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25089609P 2009-10-13 2009-10-13
PCT/EP2010/065060 WO2011045232A2 (fr) 2009-10-13 2010-10-08 Agonistes du récepteur du neuropeptide-2 (y-2r)

Publications (1)

Publication Number Publication Date
IN2012DN03042A true IN2012DN03042A (fr) 2015-07-31

Family

ID=43478048

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3042DEN2012 IN2012DN03042A (fr) 2009-10-13 2010-10-08

Country Status (7)

Country Link
US (1) US20110172147A1 (fr)
EP (1) EP2488195A2 (fr)
JP (1) JP2013507414A (fr)
CN (1) CN102596228A (fr)
CA (1) CA2776302A1 (fr)
IN (1) IN2012DN03042A (fr)
WO (1) WO2011045232A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
EP2827885B1 (fr) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions de peptides glp-1 et leur préparation
EP2708243A1 (fr) * 2012-09-17 2014-03-19 OntoChem GmbH Molécules cytotoxiques liés à un ligand de récepteur
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
EP3068795B1 (fr) 2013-11-15 2019-03-06 Novo Nordisk A/S Beta-homo arginine substitution au position 35 de hpyy(1-36)
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AU2016275735B2 (en) 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP4299118A3 (fr) 2018-02-02 2024-04-10 Novo Nordisk A/S Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
CN109678930B (zh) * 2018-12-05 2022-04-29 西北工业大学 聚乙二醇修饰的npff及其用途
CN120092752A (zh) * 2025-05-09 2025-06-06 北京大学人民医院 三叉神经痛动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB779829A (en) 1953-11-20 1957-07-24 Ciba Ltd Polyglycol ethers and their manufacture
BE667886A (fr) 1965-04-23
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5962263A (en) * 1998-01-08 1999-10-05 Incyte Pharmaceuticals, Inc. Human membrane recycling proteins
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
MX2007000883A (es) 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
WO2006049681A2 (fr) * 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Agonistes recepteur y2 neuropeptidiques selectifs
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (fr) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Agonistes du recepteur y de neuropeptide
WO2007065808A2 (fr) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Agonistes du récepteur du neuropeptide-2
WO2009035347A1 (fr) * 2007-09-11 2009-03-19 Cristina-Simona Weinberg Constructions peptidiques-lipidiques et leur utilisation pour des applications diagnostiques et thérapeutiques
CA2741921A1 (fr) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Agonistes du recepteur 2 de neuropeptide (y-2r) et leurs utilisations

Also Published As

Publication number Publication date
CN102596228A (zh) 2012-07-18
US20110172147A1 (en) 2011-07-14
EP2488195A2 (fr) 2012-08-22
WO2011045232A3 (fr) 2011-06-16
CA2776302A1 (fr) 2011-04-21
JP2013507414A (ja) 2013-03-04
WO2011045232A2 (fr) 2011-04-21

Similar Documents

Publication Publication Date Title
IN2012DN03042A (fr)
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
TW200806311A (en) Neuropeptide-2 receptor-agonists
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
MX2009011802A (es) Imidazoquinolinas con propiedades inmunomoduladoras.
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
GB0812642D0 (en) Compounds
MX2011012122A (es) Derivados de tiofeno.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
IN2012DN01233A (fr)
IN2012DN03182A (fr)
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
IN2012DN02139A (fr)
MX2012000704A (es) Agonistas de gpr119.
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
PH12013502204A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2009013501A (es) Compuestos piperidinicos y sus usos.
UA99787C2 (en) Lactams as beta secretase inhibitors